Literature DB >> 22957077

Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism.

Salvador Mena1, María L Rodríguez, Xavier Ponsoda, José M Estrela, Marja Jäättela, Angel L Ortega.   

Abstract

The phenolic phytoalexin resveratrol is well known for its health-promoting and anticancer properties. Its potential benefits are, however, limited due to its low bioavailability. Pterostilbene, a natural dimethoxylated analog of resveratrol, presents higher anticancer activity than resveratrol. The mechanisms by which this polyphenol acts against cancer cells are, however, unclear. Here, we show that pterostilbene effectively inhibits cancer cell growth and stimulates apoptosis and autophagosome accumulation in cancer cells of various origins. However, these mechanisms are not determinant in cell demise. Pterostilbene promotes cancer cell death via a mechanism involving lysosomal membrane permeabilization. Different grades of susceptibility were observed among the different cancer cells depending on their lysosomal heat shock protein 70 (HSP70) content, a known stabilizer of lysosomal membranes. A375 melanoma and A549 lung cancer cells with low levels of HSP70 showed high susceptibility to pterostilbene, whereas HT29 colon and MCF7 breast cancer cells with higher levels of HSP70 were more resistant. Inhibition of HSP70 expression increased susceptibility of HT29 colon and MCF7 breast cancer cells to pterostilbene. Our data indicate that lysosomal membrane permeabilization is the main cell death pathway triggered by pterostilbene.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22957077      PMCID: PMC3434130          DOI: 10.1371/journal.pone.0044524

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Polyphenols form an extensive group of natural molecules with potential benefits for human health, e.g. cardiac protection, anticancer activities and diabetes control. The mechanisms underlying their anticancer activity have been extensively studied and include anti-oxidative, pro-apoptotic, pro-autophagic, DNA damaging, anti-angiogenic, and immunostimulatory effects. Resveratrol (Res), the most investigated polyphenol, shows a clear anticancer activity by both apoptotic and nonapoptotic mechanisms [1]. However, its low bioavailability (e.g. a 14.4 minutes half-life in the rabbit blood circulation after intravenous administration of 20 mg/kg) strongly limits its in vivo use [2]. Pterostilbene (3,5-dimethoxi-4′-hydroxystilbene; Pter) is a natural analogue of Res found in different plants such as grapes, blueberries and narra tree [3]. This natural phenolic phytoalexin, whose half-life in the blood stream is approximately five times higher than that of Res, displays potent fungicidal activity and similar or even more potent antitumor activitiy than Res [4]. The main problem in cancer treatment is to remove pools of cells capable of developing immunogenic, chemotherapeutic, and radiotherapeutic resistance. Apoptotic evasion represents one of the major obstacles since many classical antitumor agents trigger caspase-mediated apoptotic cell death [5]. Accordingly, new antitumoral strategies based on nonapoptotic mechanisms have been developed in the last years, and autophagy, lysosomal cell death and necrosis have emerged as alternative cell death programs in cancer cells [6]–[8]. Lysosomal volume and trafficking, as well as the expression of lysosomal hydrolases, are notoriously altered in transformed cells [9]. In fact, effective invasive growth and neoangiogenesis depend on these alterations [10]. Moreover, development of multidrug resistance has been also linked to the alterations in the endosome-lysosomal compartment [11]. In this sense, agents targeting lysosomes may provide means to revert multidrug resistance. Furthermore, lysosomal membrane permeabilization has recently emerged as an effective inducer of caspase-dependent and -independent cell death [12], and several inducers of lysosomal membrane permeabilization are presently under development as anti-cancer drugs. For example, siramesine (a piperidine analogue originally developed as an antidepressant) and BAMLET (a complex of bovine lactalbumin and oleic acid), can trigger lysosomal membrane permeabilization and non-apoptotic cell death even in apoptosis resistant cancer cells [7], [13]. Apoptosis and autophagy have been postulated as main cell death mechanisms induced by Res i.e., [1], [14], [15]. Nevertheless, the anticancer mechanisms induced by Pter remain unclear. In agreement with other studies we show here that Pter induces growth arrest and cancer cell death [16]. Although Pter can activate apoptosis, we show that this pathway is not essential for its cytotoxic effect. Our results show that Pter induces destabilization of the lysosomal membranes and release of lysosomal hydrolases into the cytoplasm, thus leading to the activation of a caspase-independent lysosomal cell death program.

Materials and Methods

Cell Culture and Treatments

The cell lines were purchased from the American Type Culture Collection (ATCC). Human melanoma A375, human lung carcinoma A549, and human colon adenocarcinoma HT29 were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen), and human breast adenocarcinoma MCF-7 in RPMI-1640 medium (Invitrogen). The mediums were supplemented with 10% heat-inactivated fetal bovine serum (FBS, Invitrogen), 100 units/ml penicillin (Invitrogen), and 100 µl/ml streptomycin (Invitrogen). Cells were grown under standard cell culture conditions (37°C, 5% CO2/95% air atmosphere) at a density of 20,000 cells/cm2. Cancer cells were plated and allowed to attach for 24 h. Then cells were treated with Res (Sigma-Aldrich) or Pter (Green Molecular) for 24, 48, and/or 72 h.

Cell Growth Analysis and IC50 Determination

Cell growth was analyzed using the Countess Automated Cell Counter (Invitrogen). To evaluate IC50s in the presence of Pter or Res we used the Sulphorhodamine B Toxicology Assay Kit following manufacturer’s instructions (Sigma-Aldrich) and U.S. NCI recommendations. Briefly, cells were seeded in 96-well plates (5,000 cells/well) and treated with Pter or Res (Sigma-Aldrich) (0–200 µM). Forty-eight hours after polyphenols addition cells were fixed with 10% trichloroacetic acid. Cell viability was determined by cellular staining with sulforhodamine B (0.4%) in acetic acid (1%). Viability data were represented in semilog dose-response curves. The IC50 values were calculated with Prism GraphPad software, where the IC50 value represents the concentration of the test item that induces a response halfway between the baseline and a maximum response.

Flow Cytometric Analyses

Cells were treated with polyphenols for 24 h, washed in phosphate buffered saline (PBS), trypsinized, collected with cold PBS, pelleted (1,000 g for 2 minutes), fixed with 70% chilled ethanol, and kept at 4°C overnight. Then these cells were pelleted and washed once in PBS before DNA staining with propidium iodide (Sigma-Aldrich), in the presence of RNase for 15 minutes. Analysis of apoptotic and necrotic cell death was carried out according to manufacturer instructions using Annexin V Alexa Fluor 488 (Invitrogen) and propidium iodide. Briefly, cancer cells were seeded and, 24 h later, were treated with different concentrations of Pter or Res. After 48 h in the presence of polyphenols cells were harvested and washed once in PBS, then incubated with a solution containing Annexin V Alexa Fluor 488 in a buffer containing propidium iodide. Lysosomal membrane integrity was evaluated using acridin orange. In these experiments after Pter treatment (see above) cells were stained with 2 µg/ml acridine orange (Invitrogen) which was present in the culture medium for 15 minutes. The DNA cellular content, cell death analysis and lysosomal membrane integrity was analyzed with a BD FACSCanto II flow cytometer (10,000 cell events were collected per sample).

5-Bromo-2′-Deoxyuridine Incorporation Assay

Proliferation assays were done using the Roche Cell Proliferation ELISA BrdU kit according to manufacturer’s instructions. Cells were plated in 96-well microplates and, 24 h later, treated with Pter for 4 h. Then, cells were labeled by the addition of BrdU (10 µM/well) for another 2 h. After that, cells were fixed and DNA was denatured with FixDenat solution (200 µl for 30 minutes) at room temperature. Finally, antiBrdU-POD solution was added for 90 minutes. Using a TMB-like substrate, immune complexes were detected by measuring the absorbance at 370 nm and 492 nm using a Multiskan® Spectrum (Thermo scientific).

Caspase Activity Assay

Detection of caspase-3/7 activity was performed with the Apo-One Homogeneous Caspase-3/7 Assay Kit (Promega) according to manufacturer instructions. The assay was configured for 96 well plates (5,000 cells/well). Capase-3/7 activities were evaluated 24 and 48 h after polyphenols addition. This assay provides a profluorescent substrate (Z-DEVD-R110) which is cleaved by caspase-3/7 activity to generate the fluorescent rhodamine 110. Fluorescence was measured by a Fluoroskan Ascent FL (Thermo Labsystems) (excitation at 485 nm; emission at 538 nm).

Protein Extraction and Western Blot Analysis

After experimental treatments cells were rinsed twice with cold PBS. Then, proteins were extracted from cultured cells by scraping in ice-cold lysis buffer (CelLytic™ MT Mammalian Tissue Lysis/Extraction Reagent, Sigma-Aldrich) containing a protease and phosphatase inhibitors cocktail (Sigma-Aldrich). Equal amounts of extracted proteins (30 µg/condition) were resolved using a criterion XT bis-tris 4–12% gel (Bio-rad) and transferred to an Immun-Blot™ PVDF membrane (Invitrogen). Blots were incubated overnight at 4°C, separately, with the primary antibodies: Rabbit polyclonal LC3A/B antibody (1∶500) (Abcam); rabbit monoclonal GAPDH antibody (1∶1,000) (Cell signaling); rabbit monoclonal p62 antibody (1∶1,000) (Sigma-Aldrich); rabbit monoclonal HSP70 antibody (1∶200) (Enzo Life Science). Blots were incubated for 1 h at room temperature with the appropriate peroxidase-conjugated secondary antibody: Anti-rabbit IgG HRP-linked antibody (1∶1,000) (Cell signaling). Blots were visualized using a chemiluminescence detection kit ECL western blotting substrate (Pierce, Thermo Scientific) and the signals were captured using a ChemiDoc™ XRS+Imaging System (Bio-Rad). The density of the bands was measured using Image Lab Software™ version 2.0.1 (Bio-Rad).

Confocal and Fluorescence Microscopy

A375-, A549-, MCF7-, and HT29-GFP-LC3 cells were seeded out on coverslips in 24-well plates and allowed to attach for 24 h. Then cells were treated with Pter (50 µM) for 24 h, or with Concanamycin A (2 nM) (Sigma-Aldrich) or Rapamycin (100 nM) (Sigma-Aldrich) for 1 h. Both control and treated cells were fixed with paraformaldehyde (PFA) 4% for 10 minutes at 4°C. Cells were washed twice with DPBS (Invitrogen), mounted on microscope slides with ProLong Gold antifade reagent (Invitrogen), and, then, were visualized using a confocal laser microscope (Leica TCS Sp2). Lysosomal visualization was carried out after Pter treatment using the fluorophore Lysotracker Red (Invitrogen). Briefly, cells were seeded in 6-well cell culture plates. After 24 h of treatment with Pter cells were stained according to manufacturer recommendations (75 nM, 30 minutes) and imaged with a Nikon Diaphot inverted microscope.

Lactate Dehydrogenase Assay

Cytotoxicity induction was determined by measuring lactate dehydrogenase (LDH) activity released to the extracellular medium. The LDH release assay was performed using a citotoxicity detection kitplus (LDH) (Roche Diagnostics) according to the manufacturer’s instructions. This kit determines spectrophotometrically the amount of reduced formazan at 490 nm. This measurement was done with a Multiskan Spectrum (Thermo scientific). The LDH content of each sample was calculated according to the following formula: Cytotoxicity (%) = [(experimental value − low control)/(high control − low control)] × 100.

Cathepsin Activity Assays

Cancer cell lines were seeded in six well-plates (0.2×106 cells/well) and, 24 h later, were treated with Pter (0–100 µM). After removal of the medium, extraction buffer containing different concentrations of digitonin (Sigma-Aldrich) was used to separate cytosolic (20 µg/ml) and total (200 µg/ml) cathepsins. When necessary, the concentration of digitonin was optimized for different cell types. Cells were incubated with extraction buffer for 15 minutes at 4°C on a rocking platform. Cysteine and aspartate cathepsin activities were measured using the fluorescent substrates z-fr-AFC (AFC = 7-Amino-4-trifluoromethylcoumarin) (excitation at 405 nm; emission at 510 nm) (Enzo Life Sciences) and Mca-GKPILFFRLK(Dnp)-DR-NH2 [Mca =  (7-methoxycoumarin-4-yl)acetyl; Dnp = dinitrophenyl] (excitation at 320 nm; emission at 420 nm) (Enzo Life Sciences), respectively. Pepstatin A (5 µg/ml) (Sigma-Aldrich) and Leupeptin (50 µg/ml) (Sigma-Aldrich) were used to inhibit the activity of aspartyl peptidases and serine-cysteine proteases, respectively.

Electron Microscopy

Cell monolayers were fixed with 2% glutardaldehyde in 0.1 M phosphate buffer, pH 7.4, for 30 minutes, and with 2% osmium tetroxide in water for 1 h. Then, samples were dehydrated with ethanol and counterstained with uranyl acetate, and finally embedded in TAAB resin (T002, Taab Laboratories). Cells were sectioned at 2 µm and stained with toluidine blue. Selected semithin sections were re-embedded and trimmed for ultrathin sectioning. Ultrathin sections were stained with lead citrate and examined in a Jeol JEM-1010 electron microscope.

siRNA Transfection

Cells were transfected with siRNA targeting HSPA1A and HSPA1B (ON-TARGETplus SMARTpool, Dharmacon Research, USA) at a final concentration of 25 nM per well. As positive control we used a siRNA against glyceraldehyde phosphate dehydrogenase (ON TARGETplus GAPDH Control Pool, Dharmacon Research, USA). To account for the nonsequence-specific effects, siControl Non-Targeting Pool from Dharmacon was used. MCF7 and HT29 cell lines were seeded on 12-well plates (75,000 cells/well) one day prior to transfection. DharmaFECT 1 siRNA Transfection Reagent (3 µl) was added to 98 µl of serum free medium and incubated at room temperature for 5 minutes. Hsp70, negative or positive control siRNA (100 µl) were added and incubated for another 20 minutes. The transfection reagent/siRNA complex was mixed with 1 ml of DMEM with 10% FBS and added to the cells. After siRNA addition, the cells were incubated at standard culture conditions (37°C, 5% CO2).

Statistical Analyses

Values are expressed as the mean ± SD. All experiments were repeated at least three independent times. Data were analyzed using the Graph Pad Prism version 5.00. The significance of the difference between the control and each experimental test condition was analyzed by Student’s t test or one way ANOVA followed by a Tukey-test. A value of P<0.05 was considered significant.

Results

Pterostilbene Shows Higher Anticancer Potential than Resveratrol

Structural modifications of the Res molecule can increase its in vivo half-life without causing toxic side-effects in normal tissues [17]. Treatment of human A375 (melanoma), MCF7 (breast adenocarcinoma), A549 (lung cancer) and HT29 (colon cancer) cells with Pter reduced tumor cell number in vitro in a concentration- and time-dependent manner (Figure 1). IC50s determined by Sulphorhodamine B showed that the growth inhibitory effect of Pter was cell type-dependent, being much lower for HT29 (Pter IC50 = 60,3 µmol/L; Res IC50 = 71,9 µmol/L) and MCF7 (Pter IC50 = 44,0 µmol/L; Res IC50 = 56,6 µmol/L) cells than for A375 (Pter IC50 = 14,7 µmol/L; Res IC50 = 25,5 µmol/L) and A549 (Pter IC50 = 28,6 µmol/L; Res IC50 = 36,2 µmol/L) cells. Notably, the IC50 values were lower for Pter than for Res in all cases.
Figure 1

Effect of pterostilbene and resveratrol on tumor cell growth in vitro.

A375, A549, HT29 and MCF7 cells were incubated for 24, 48 or 72 h with indicated concentrations of Pter or Res. Actual cell number was analyzed using the Countess Automated Cell Counter. Results were expressed as relative proliferation index ± SD (n = 4) where control is 100% (*P<0.05).

Effect of pterostilbene and resveratrol on tumor cell growth in vitro.

A375, A549, HT29 and MCF7 cells were incubated for 24, 48 or 72 h with indicated concentrations of Pter or Res. Actual cell number was analyzed using the Countess Automated Cell Counter. Results were expressed as relative proliferation index ± SD (n = 4) where control is 100% (*P<0.05).

Pterostilbene Induces Cell Cycle Arrest and Blocks DNA Synthesis

Microscopic analysis (data not shown) and data presented above clearly showed that Pter induced cell death in all cancer cell lines studied. In order to test whether the cell death was preceded or accompanied by a growth arrest, we analyzed the effect of Pter on cell cycle distribution at the 24 h time point. A375 and A549 cells showed an arrest in the S phase of the cell cycle after 24 h of treatment with 20 µM Pter (Figure 2A). A similar S phase arrest was observed in HT29 cells upon treatment with 75 µM Pter, and also MCF7 cells treated with 10–20 µM Pter showed a tendency to arrest in the S phase (Figure 2A). Notably, higher concentration (75 µM) of Pter significantly reduced the portion of A375 cells in the S phase suggesting that the cells arrested in the S phase before succumbing (Figure 2A).
Figure 2

Effect of pterostilbene on cell cycle distribution and DNA synthesis.

A) Tumor cells were seeded in six well-plates and treated 24 h later with indicated concentrations of Pter. After 24 h, cells were fixed and stained with propidium iodide as explained under material and methods. The DNA content of the cells was analyzed by flow cytometry (10,000 cell events were collected per sample). Representative cell cycle histograms for Control and Pter-treated cells are shown. Results are expressed as % of total cells ± SD (n = 3) (*p<0.05 Vs. Control). B) DNA synthesis was evaluated by BrdU incorporation after 4 h of incubation with Pter followed by 2 h with Pter and 10 µM BrdU.

Effect of pterostilbene on cell cycle distribution and DNA synthesis.

A) Tumor cells were seeded in six well-plates and treated 24 h later with indicated concentrations of Pter. After 24 h, cells were fixed and stained with propidium iodide as explained under material and methods. The DNA content of the cells was analyzed by flow cytometry (10,000 cell events were collected per sample). Representative cell cycle histograms for Control and Pter-treated cells are shown. Results are expressed as % of total cells ± SD (n = 3) (*p<0.05 Vs. Control). B) DNA synthesis was evaluated by BrdU incorporation after 4 h of incubation with Pter followed by 2 h with Pter and 10 µM BrdU. To evaluate the effect of Pter on DNA synthesis we measured the ability of cells to incorporate BrdU after 4 h incubation with increasing concentrations of Pter. Akin to earlier reports on Res and other polyphenols [14], [15], [18], Pter reduced the BrdU incorporation in a concentration-dependent fashion in all cell lines.

Cell Death Induction by Pterostilbene is Time- and Concentration-Dependent

The molecular mechanisms underlying the anticancer effects of natural polyphenols are poorly defined. Res has been shown to be a potent inducer of both apoptosis [1], [14] and autophagy [1], [15], as well as a carcinogenesis inhibitor [19], [20]. However, anticancer mechanisms of its dimethylated analog, Pter, have not been extensively analyzed. For this purpose we investigated the ability of Pter ability to induce apoptosis, autophagy and necrosis. First, we measured the activity of apoptotic effector caspases 3 and 7 (DEVDase activity) in cancer cells treated with Pter. Pter induced a significant caspase 3/7 activation in A375 and A549 cells, but not in HT29 and MCF7 cells (Figure 3A). Accordingly, Pter induced the translocation of annexin V to the cell surface (marker of apoptosis) only in A375 and A549 cells (Figure 3B). To evaluate the contribution of apoptosis on cell death induction we used a cell-permeable pan-caspase inhibitor z-VADfmk. Notably, z-VAD-fmk failed to inhibit the Pter-induced reduction in cell number (Figure 3C). Positive controls of apoptosis and zVADfmk inhibition capability are shown in Supporting Information (Figure S1). These results suggest that caspase-independent mechanisms may play a role in Pter-induced cytotoxicity.
Figure 3

Pter induces caspase-independent cell death.

A) Caspase-3/7 (DEVDase) activities were evaluated 24 and 48 h after addition of Pter. Results are expressed as a relative index of fluorescence ± SD (n = 3) when compared with control (100%). The results were statistically analyzed by ANOVA and contrasted by the Tukey test (*p<0.001; **p<0.01 Vs. Control). B) Induction of apoptosis was assayed by staining with Annexin V. The total percentage of Annexin V-positive cells was determined by flow cytometry 48 h after treatment with DMSO or with increasing concentrations of Pter (*p<0.001 Vs. Control). C) Effect of Pter on tumor cell number in the presence of 20 µM pancaspase inhibitor zVAD fmk, which was added 1 h prior to the addition of 50 µM Pter or vehicle (1.5 µl/ml DMSO). Cell number was analyzed 24 and 48 h later. Results are expressed as relative proliferation index ± SD (n = 3) where control is 100%.

Pter induces caspase-independent cell death.

A) Caspase-3/7 (DEVDase) activities were evaluated 24 and 48 h after addition of Pter. Results are expressed as a relative index of fluorescence ± SD (n = 3) when compared with control (100%). The results were statistically analyzed by ANOVA and contrasted by the Tukey test (*p<0.001; **p<0.01 Vs. Control). B) Induction of apoptosis was assayed by staining with Annexin V. The total percentage of Annexin V-positive cells was determined by flow cytometry 48 h after treatment with DMSO or with increasing concentrations of Pter (*p<0.001 Vs. Control). C) Effect of Pter on tumor cell number in the presence of 20 µM pancaspase inhibitor zVAD fmk, which was added 1 h prior to the addition of 50 µM Pter or vehicle (1.5 µl/ml DMSO). Cell number was analyzed 24 and 48 h later. Results are expressed as relative proliferation index ± SD (n = 3) where control is 100%. To investigate the involvement of autophagy in Pter-induced cytotoxicity, we analyzed the levels of LC3II and P62/SQSTM1 that should increase and decrease, respectively, upon autophagy induction [21], [22]. Notably, 24 h treatment with Pter induced a concentration-dependent accumulation of both LC3II (Figure 4A) and P62 (Figure 4B) proteins in all four cell lines as analyzed by immunoblotting. Furthermore, confocal and fluorescence microscopy of A375, A549, MCF7, and HT29 cells expressing a GFP-tagged LC3 revealed a clear increase in the number of large LC3-positive vesicles upon 24 h treatment with Pter (Figures 4A bottom, and 4C). Visualization of numerous large (diameter up to 2 µm) vesicles surrounded by a double membrane by transmission electron microscopy confirmed that these vesicles are enlarged autophagosomes (Figure 4C). These results are suggestive of autophagosome accumulation due to inhibited autophagic flux [22].
Figure 4

Effects of pterostilbene on autophagic flux.

Proteins were detected by western blot with LC3A/B (A) or SQSTM1/p62 antibodies (B). Graphic shows the percentage of induction of eGFP-LC3 punctuation/aggregation in control and Pter (50 µM) conditions after 24 h of treatment (A). Densitometric analysis of SQSTM1/p62 correlated with GAPDH levels. The ratio in untreated control cells was set to 100% (B). MCF7-eGFP-LC3 cells were visualized by confocal and transmission electronic microscopy after treatment with 50 µM Pter for 24 h or 100 nM Rapamycin for 1 h (C).

Effects of pterostilbene on autophagic flux.

Proteins were detected by western blot with LC3A/B (A) or SQSTM1/p62 antibodies (B). Graphic shows the percentage of induction of eGFP-LC3 punctuation/aggregation in control and Pter (50 µM) conditions after 24 h of treatment (A). Densitometric analysis of SQSTM1/p62 correlated with GAPDH levels. The ratio in untreated control cells was set to 100% (B). MCF7-eGFP-LC3 cells were visualized by confocal and transmission electronic microscopy after treatment with 50 µM Pter for 24 h or 100 nM Rapamycin for 1 h (C). To determine the ability of Pter to induce necrotic cell death, we investigated the integrity of the plasma membrane by measuring the release of cytosolic lactate dehydrogenase (LDH) to the culture supernatant [23]. The LDH release was stimulated in all cell lines after 24 h treatment with Pter at concentrations≥50 µM (Figure 5A). Akin, flow cytometry analyses with Annexin V-FITC and propidium iodide showed just a moderate necrosis increase in A375 and A549 (Figure 5B). Although, LDH release was increased after 48 and 72 h of Pter treatment (Figure 5A), inhibition of necroptosis, a serine–threonine kinase receptor-interacting protein 1 (RIP1) dependent form of necrosis [24], did not affect Pter-induced cell death (Figure 5 C). Thus indicating that other type of cell death induction different of apoptosis, autophagy, and necrosis may be activated by Pter. Positive controls showing the capability of necrostatin-1 to inhibit necroptotic cell death are shown in Supporting Information (Figure S2).
Figure 5

Effect of pterostilbene on necrosis induction.

A) Release of LDH activity to the extracellular medium. Cells were exposed to Pter for 24, 48 and 72 h. Results are expressed as relative LDH activities ± SD (n = 3) where control was set to 100%. B) Propidium iodide fluorescence was plotted against annexin-V fluorescence 24 h after treatment. Results are expressed as total percentage of necrotic cells ± SD (n = 3). C) Effect of Pter on tumor cell number in the presence of the necroptosis inhibitor 5-(Indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin (Nec-1, Calbiochem). Nec-1 25 µM was added 1 h prior to the addition of 50 µM Pter. Cell number was analyzed 24 and 48 h later. Results are expressed as relative proliferation index ± SD (n = 3) where control is 100%. The results were statistically analyzed by ANOVA and contrasted by the Tukey test (***p<0.001; **p<0.01; *p<0.05 Vs. Control).

Effect of pterostilbene on necrosis induction.

A) Release of LDH activity to the extracellular medium. Cells were exposed to Pter for 24, 48 and 72 h. Results are expressed as relative LDH activities ± SD (n = 3) where control was set to 100%. B) Propidium iodide fluorescence was plotted against annexin-V fluorescence 24 h after treatment. Results are expressed as total percentage of necrotic cells ± SD (n = 3). C) Effect of Pter on tumor cell number in the presence of the necroptosis inhibitor 5-(Indol-3-ylmethyl)-(2-thio-3-methyl)hydantoin (Nec-1, Calbiochem). Nec-1 25 µM was added 1 h prior to the addition of 50 µM Pter. Cell number was analyzed 24 and 48 h later. Results are expressed as relative proliferation index ± SD (n = 3) where control is 100%. The results were statistically analyzed by ANOVA and contrasted by the Tukey test (***p<0.001; **p<0.01; *p<0.05 Vs. Control).

Pterostilbene Induces Lysosomal Membrane Alterations

Lysosomal leakage has been described as an inducer of cell death [7], [25], and lysosomal destabilization has been shown to be a common consequence of microtubule-targeting drugs [26]. Thus, to further elucidate the mechanisms underlying Pter-induced cancer cell death, we studied its possible effects on lysosomes. For this purpose we evaluated lysosomal membrane alterations by different methods. First, lysosomal volume was assayed using acridine orange staining and flow cytometry 24 h after exposure to Pter. Acridine orange is a metachromatic fluorescent cationic dye that emits red light when in high concentration inside the lysosomes, and green light in the cytosol and nucleus where it mainly stains DNA and RNA and is less concentrated than in acidic lysosomes. We evaluated the red fluorescence as an indicator of lysosomal volume [27]. Significant increases in red fluorescence were observed in all tumor cell lines upon treatment with Pter 50 µM (Figure 6A). As shown by fluorescence microscopy of cells stained with lysotracker, Pter induced an increase in the number and/or size of lysosomes (Figure 6B) We observed that these changes were higher in A375 and A549 than in HT29 and MCF7 cells (Figure 6A, B).
Figure 6

Pterostilbene induces lysosomal membrane permeabilization.

A) Flow cytometry analysis of acridine orange staining after 24 h incubation with indicated concentrations of Pter. Increases in red fluorescence (x-axis), observed in treated cells, indicated changes at the lysosomal membrane. B) Microscopic images of Lysotracker red-stained cells untreated or treated with indicated concentrations of Pter for 24 h. C) Cytosolic cysteine cathepsin (zFRase) activity expressed as percentage of total activity (n = 7) was measured 24 h after Pter addition. D) Cytosolic aspartyl cathepsin activity expressed as percentage of total activity (n = 7) after 24 h of Pter treatment. The results were statistically analyzed by ANOVA and the Tukey test (*p<0.05; **p<0.01; ***p<0.001 vs. control). E) Cathepsins B and D inhibitors, Leupeptin and Pepstatin A, were added 1 h prior to the addition of 50 µM Pter. Cell number was analyzed 24 h later.

Pterostilbene induces lysosomal membrane permeabilization.

A) Flow cytometry analysis of acridine orange staining after 24 h incubation with indicated concentrations of Pter. Increases in red fluorescence (x-axis), observed in treated cells, indicated changes at the lysosomal membrane. B) Microscopic images of Lysotracker red-stained cells untreated or treated with indicated concentrations of Pter for 24 h. C) Cytosolic cysteine cathepsin (zFRase) activity expressed as percentage of total activity (n = 7) was measured 24 h after Pter addition. D) Cytosolic aspartyl cathepsin activity expressed as percentage of total activity (n = 7) after 24 h of Pter treatment. The results were statistically analyzed by ANOVA and the Tukey test (*p<0.05; **p<0.01; ***p<0.001 vs. control). E) Cathepsins B and D inhibitors, Leupeptin and Pepstatin A, were added 1 h prior to the addition of 50 µM Pter. Cell number was analyzed 24 h later. Next, we analyzed the release of lysosomal cysteine (B, L and H) and aspartate (D and E) cathepsins to the cytosol as a marker of lysosomal membrane permeabilization. Remarkably, Pter caused a concentration-dependent increase in the cytosolic cathepsin activities in all four cell lines without affecting the total cellular activities after 24 h of treatment (Figure 6C, D). To determine the contribution of cysteine (B, L, and H) and aspartate (D, and E) cathepsins to cell death, we inhibited the activity of aspartyl peptidases with pepstatin A, and the serine cysteine proteases with leupeptin. As shown in Figure 6E Pter induced the same effect in the presence or absence of these enzyme inhibitors.

Tumor Resistance to Pterostilbene Correlates with HSP70 Cellular Levels

Heat shock protein 70 (HSP70) is an evolutionary conserved protein that promotes the survival of stressed cells, where stabilization of lysosomal membranes is one of the protective mechanisms [28]. Different studies have shown a relationship between Res and HSP70 expression, although taking into account the protector role of the protein, HSP70 levels could regulate the distinct grade of susceptibility shown by the tumor cell lines. To characterize the higher resistance of HT29 and MCF7 to Pter treatment (Figure 1, Figure 2, Figure 3A, B and Figure 4C) we analyzed the possible involvement of HSP70. As shown in Figure 7A, Hsp70 levels were found to be higher in HT29 and MCF7 cells than in A375 and A549. Moreover, siRNA-mediated reduction of HSP70 in HT29 and MCF7 (Figure 7B) cells resulted in a marked cell death induction (Figure 7C) and a higher lysosomal membrane susceptibility to Pter (Figure 7D). Therefore, HSP70 levels, indeed, correlate with the sensitivity of the tumor cells to Pter-induced cytotoxicity.
Figure 7

HSP70 depletion sensitizes cells to Pter.

A) Representative HSP70 and GAPDH (loading control) immunoblots of proteins extracted from indicated cells. Densitometric analysis of the immunoblots (n = 3) are shown below. B) Inhibition of HSP70 expression by siRNA. Cells were transfected with HSP70 siRNA or GAPDH SiRNA (positive control). Protein levels were measured by western blotting. C) HT29 and MCF7 cells were seeded and transfected with HSP70 siRNA 24 h later. Pter was added at 24 h post-transfection. Cell viability was performed by sulforhodamine B colorimetric assay 48 h later. The number of replicates per experiment was at least six (n = 3). The results were statistically analyzed by ANOVA and the Tukey test (*p<0.05; ***p<0.001 vs. control). D) Cysteine and aspartyl cathepsins were determined in HT29 and MCF7 cells 72 h post- HSP70 siRNA transfection and 24 h after Pter treatment (n = 6). The results were statistically analyzed by ANOVA and the Tukey test (***p<0.001 vs. Pter 50µM).

HSP70 depletion sensitizes cells to Pter.

A) Representative HSP70 and GAPDH (loading control) immunoblots of proteins extracted from indicated cells. Densitometric analysis of the immunoblots (n = 3) are shown below. B) Inhibition of HSP70 expression by siRNA. Cells were transfected with HSP70 siRNA or GAPDH SiRNA (positive control). Protein levels were measured by western blotting. C) HT29 and MCF7 cells were seeded and transfected with HSP70 siRNA 24 h later. Pter was added at 24 h post-transfection. Cell viability was performed by sulforhodamine B colorimetric assay 48 h later. The number of replicates per experiment was at least six (n = 3). The results were statistically analyzed by ANOVA and the Tukey test (*p<0.05; ***p<0.001 vs. control). D) Cysteine and aspartyl cathepsins were determined in HT29 and MCF7 cells 72 h post- HSP70 siRNA transfection and 24 h after Pter treatment (n = 6). The results were statistically analyzed by ANOVA and the Tukey test (***p<0.001 vs. Pter 50µM).

Discussion

Cancer is a genetic and epigenetic disease which is associated with unlimited replicative potential, reduced dependence on growth-promoting signals, resistance to growth-inhibitory signaling, evasion of cell death activation, sustained angiogenesis, as well as the ability for tissue invasion and metastatic spread [5]. Although new therapies may extend patients’ lives for days, months, or even years, the quality of life added is in most cases questionable. Thus, the development of therapies that could improve efficacy without compromising a reasonable quality of life, are urgently required. It is in this particular sense that natural polyphenols may offer some hope [29]. Anticancer mechanisms elicited by natural polyphenols have been extensively studied in the last years. However, reported effects claimed for polyphenols must be carefully evaluated since large differences, even controversial, are found depending on experimentals [29]. Res, one of the most studied polyphenols, shows the ability to induce apoptosis and autophagy, and has antiproliferative effects [1], [14], [15], [30], [31]. However, its antioxidant properties may potentially reduce oxidative stress thereby inhibiting apoptosis and enhancing cell survival [32]. Although potent anticancer effects have been shown in cultured cells, potential inhibition of cancer growth by Res in vivo is strongly limited due to its low bioavailability [2]. Therefore, it is important to take into consideration other chemical structures, which may preserve anticancer properties while having higher bioavailability. It is in this context that Pter, a natural dimethylated analog of Res with a longer half-life [29], represent an attractive option. Pter showed higher anticancer effects than Res in all the tumor cell lines assayed (Figure 1). Nevertheless, A375 melanoma and A549 lung cancer cells were more susceptible to the anticancer action than HT29 colon cancer and MCF7 breast cancer cells. Thus suggesting that, the reduction in tumor cell number induced by Pter depends on differences in the cell lines assayed. To assay if pterostilbene shows a preferential effect on cancer cell lines versus their normal counterparts we used normal human primary epidermal melanocytes from neonatal foreskin and epithelial lung cells (BEAS2B). The growth inhibitory effect in vitro was determined by Sulphorhodamine B and showed that Pter’s IC50 for melanocytes (Pter IC50 = 52,1 µmol/L) was similar to that found for breast (MCF7) and colon (HT29) cancer cell lines (see Results section). Whereas epithelial lung cells showed a much lower IC50 value (Pter’s IC50 = 1,8 µmol/L), but again similar to those found for A375 or A549 cells. Nevertheless, this is no surprise. Different polyphenols, such as e.g. resveratrol, curcumin, green tea polyphenols, or pterostilbene, have anticancer activity in vivo but without showing any relevant toxicity for the host at therapeutic effective doses (e.g. [4], [33], [34]). Naturally this apparent biological paradox is intriguing. However it seems obvious that under in vivo conditions other mechanisms, besides polyphenols (but related to), play a relevant role. In this sense the tumor microenvironment is of particular interest. For instance, in a previous report, we showed that intravenous administration to mice of pterostilbene and quercetin, two structurally related and naturally occurring small polyphenols, inhibits in vivo metastatic growth of highly malignant B16 melanoma F10 (B16–F10) cells [35]. Pterostilbene and quercetin inhibit bcl-2 expression in metastatic cells, which sensitizes them to vascular endothelium-induced cytotoxicity [35] (a physiological defense mechanism against metastatic cell invasion [36]). In addition polyphenols increased endothelial NO synthase expression in the vascular endothelium, thus favoring endothelial NO-induced tumor cell cytotoxicity during the process of cancer cell-vascular endothelium interaction [35]. A complex network of intercellular signaling mechanisms, as well as intracellular signaling cascades, may also regulate these interactions within the metastatic microenvironment [37]. This hypothesis opens a fantastic array of possibilities which, although far beyond the scope of a single paper, deserve further research. Polyphenols like Pter show potent cytostatic effects [38], [39]. Although, in our experiments we detected lower DNA synthesis capability and cell cycle arrest in S phase (Figure 2A, B), as suggested by others [40], the high reduction in cell number elicited by Pter can be only understood if cell death mechanisms are activated. Apoptosis has been previously postulated as the main cell death program activated by Pter [38], [40], [41]. However, concentrations unreachable under in vivo conditions have been usually tested in vitro (≥75 µM). We evaluated the possible contribution of apoptotic cell death by analyzing caspase 3/7 activity and the consequence of their inhibition on the rate of tumor cell growth. Although, caspases are clearly activated by Pter in A375 and A549 cells, pre-incubation with the pancaspase inhibitor zVADfmk was unable to reduce cell death induction (Figure 3A, C). Moreover, HT-29 and MCF7 cells, latter of which do not express caspase-3 [42], failed to activate effector caspases and induce apoptotic caspase-dependent cell death upon Pter treatment (Figure 3A, B). These results suggest that Pter-induced cell death may also occur via caspase-independent mechanism. For this reason we investigated the role of other types of cell death in Pter-induced cytotoxicity. Macroautophagy (hereafter referred to as autophagy) is an essential conserved cellular process by which lysosomes degrade and recycle damaged organelles and macromolecules and maintain cellular energy levels under nutrient and growth factor deficiency [43], [44]. Although this process regulates the cellular energy homeostasis during nutrient limitation, autophagy may also represent an independent mode of programmed cell death [45], [46]. Indeed, autophagy activation has been proposed as an alternative mechanism of cell death induced by polyphenols [15], [40]. However, contradictory results are presented in the literature [47]. Our data show that Pter induces an accumulation of autophagosomes (Figure 4C) as well as the conversion of cytosolic LC3-I to its lipidated membrane-associated form LC3-II (Figure 4A). Because LC3-II itself is degraded by autophagy, the relative amount of LC3 at a single time point alone, does not necessarily indicate an increase in autophagic flux [22]. P62/sequestosome 1 is a common component of protein aggregates being degraded by autophagy [48], and thus the expression level of this protein serves as a complementary marker for autophagic flux. Pter induced a clear accumulation of P62/sequestosome 1 indicating an inhibition of autophagic flux (Figure 4B). Microtubules have been suggested to be essential for vesicular and autophagic traffic and consequently, vincristine treatment induces an accumulation of autophagosomes [26], [49]. This accumulation is caused by a failure in the fusion of autophagosomes with lysosomes [50], the increase in autophagosome formation rate [51], or the combination of the two [49]. LC3-II and P62/sequestosome 1 accumulation and the increment in the acidic compartment and lysosomal size suggest that fusion of autophagosomes and lysosomes is alterated. Indeed, natural polyphenols and synthetic analogs are able to inhibit tubulin polymerization acting like anti-mitotic drugs [52]. Lysosomal size alterations by different treatments have been reported to correlate with reduced lysosomal stability and sensitization to non-apoptotic cell death pathways [26], [53]. Accordingly, Pter induced an increase in the size of lysosomes, lysosomal membrane destabilization (Figure 6A, B) and intraluminal content release (Figure 6C, D). Taken together our data show that Pter-induced cytotoxicity was not primarily the consequence of classic apoptosis, autophagy, or necrosis. Recently, a lysosomal cell death program has been presented as an alternative cell death pathway for demising highly apoptosis-resistant tumor cells [7]. In this sense, we show that Pter promotes the release of lysosomal cathepsins and other hydrolases into the cytosol. Although Res has been shown capable to induce cancer cell death through lysosomal cathepsin D [54] and L [55] release, in our experiments the inhibition of lysosomal cathepsins by pharmaceutical protease inhibitors did not delay the death process (Figure 6E). Therefore, lysosomal membrane permeabilization could be an epiphenomenon of the death process or alternatively, the cytotoxic effect induced by the massive release of lysosomal hydrolases simply cannot be inhibited by blocking the activity of cathepsins D, E, B, L and H. Due to the numerous proteases present inside the lysosomes, and the impossibility to inhibit all of them simultaneously without causing massive alterations in cellular functions, we analyzed the protective effect of HSP70. Interestingly, resistance to Pter treatment correlates with cellular HSP70 levels (Figure 1 and Figure 7A). In fact, inhibition of HSP70 expression (Figure 7B) increased Pter-induced cytotoxicity (Figure 7C) and lysosomal cathepsins release (Figure 7D). Our results demonstrate that tumor cell death induction elicited by Pter is preferentially mediated through lysosomal membrane permeabilization and depends on HSP70 levels. Positive controls of apoptosis and zVADfmk inhibition capability. Activation of apoptosis and the ability of zVADfmk to inhibit the process were determined studying cleaved PARP (Cell Signaling) by western blot. Cells were treated with Camptothecin [A375 (50 nM); A549, HT29, and MCF7 (500 nM)] (A), or Pter (20 µM-50 µM) (B) for 24 and 48 h, in absence or presence of 20 µM pancaspase inhibitor zVAD fmk, which was added 1 h prior to the addition. C) Percentage of apoptotic cells after camptothecin treatment was analyzed by fluorescence microscopy in absence or presence of zVAD fmk. (TIF) Click here for additional data file. Positive controls showing the capability of necrostatin-1 to inhibit necroptotic cell death. Cells were treated with TNF-α (50 nM) or TNF-α+zVADfmk (20 µM) in presence or absence of 30 µM necrostatin-1 for 48 h to show the capability of necrostatin-1 to inhibit necroptosis. The amount of cell death induced by TNF-α was evaluated by the tripan blue exclusion assay. (TIF) Click here for additional data file.
  55 in total

1.  Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.

Authors:  N Ahmad; V M Adhami; F Afaq; D K Feyes; H Mukhtar
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

Review 2.  Natural polyphenols in cancer therapy.

Authors:  Miguel Asensi; Angel Ortega; Salvador Mena; Fatima Feddi; José M Estrela
Journal:  Crit Rev Clin Lab Sci       Date:  2011-12-05       Impact factor: 6.250

3.  Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D.

Authors:  Nicol F Trincheri; Giuseppina Nicotra; Carlo Follo; Roberta Castino; Ciro Isidoro
Journal:  Carcinogenesis       Date:  2006-11-20       Impact factor: 4.944

Review 4.  Another way to die: autophagic programmed cell death.

Authors:  Y Tsujimoto; S Shimizu
Journal:  Cell Death Differ       Date:  2005-11       Impact factor: 15.828

Review 5.  Autophagy: process and function.

Authors:  Noboru Mizushima
Journal:  Genes Dev       Date:  2007-11-15       Impact factor: 11.361

6.  Pterostilbene inhibits pancreatic cancer in vitro.

Authors:  Patrick W Mannal; Juile A Alosi; John G Schneider; Debbie E McDonald; David W McFadden
Journal:  J Gastrointest Surg       Date:  2010-02-06       Impact factor: 3.452

7.  Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma.

Authors:  Paula Ferrer; Miguel Asensi; Sonia Priego; María Benlloch; Salvador Mena; Angel Ortega; Elena Obrador; Juan M Esteve; José M Estrela
Journal:  J Biol Chem       Date:  2006-11-29       Impact factor: 5.157

Review 8.  Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies.

Authors:  Bharat B Aggarwal; Anjana Bhardwaj; Rishi S Aggarwal; Navindra P Seeram; Shishir Shishodia; Yasunari Takada
Journal:  Anticancer Res       Date:  2004 Sep-Oct       Impact factor: 2.480

Review 9.  Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.

Authors:  Daniel J Klionsky; Hagai Abeliovich; Patrizia Agostinis; Devendra K Agrawal; Gjumrakch Aliev; David S Askew; Misuzu Baba; Eric H Baehrecke; Ben A Bahr; Andrea Ballabio; Bruce A Bamber; Diane C Bassham; Ettore Bergamini; Xiaoning Bi; Martine Biard-Piechaczyk; Janice S Blum; Dale E Bredesen; Jeffrey L Brodsky; John H Brumell; Ulf T Brunk; Wilfried Bursch; Nadine Camougrand; Eduardo Cebollero; Francesco Cecconi; Yingyu Chen; Lih-Shen Chin; Augustine Choi; Charleen T Chu; Jongkyeong Chung; Peter G H Clarke; Robert S B Clark; Steven G Clarke; Corinne Clavé; John L Cleveland; Patrice Codogno; María I Colombo; Ana Coto-Montes; James M Cregg; Ana Maria Cuervo; Jayanta Debnath; Francesca Demarchi; Patrick B Dennis; Phillip A Dennis; Vojo Deretic; Rodney J Devenish; Federica Di Sano; J Fred Dice; Marian Difiglia; Savithramma Dinesh-Kumar; Clark W Distelhorst; Mojgan Djavaheri-Mergny; Frank C Dorsey; Wulf Dröge; Michel Dron; William A Dunn; Michael Duszenko; N Tony Eissa; Zvulun Elazar; Audrey Esclatine; Eeva-Liisa Eskelinen; László Fésüs; Kim D Finley; José M Fuentes; Juan Fueyo; Kozo Fujisaki; Brigitte Galliot; Fen-Biao Gao; David A Gewirtz; Spencer B Gibson; Antje Gohla; Alfred L Goldberg; Ramon Gonzalez; Cristina González-Estévez; Sharon Gorski; Roberta A Gottlieb; Dieter Häussinger; You-Wen He; Kim Heidenreich; Joseph A Hill; Maria Høyer-Hansen; Xun Hu; Wei-Pang Huang; Akiko Iwasaki; Marja Jäättelä; William T Jackson; Xuejun Jiang; Shengkan Jin; Terje Johansen; Jae U Jung; Motoni Kadowaki; Chanhee Kang; Ameeta Kelekar; David H Kessel; Jan A K W Kiel; Hong Pyo Kim; Adi Kimchi; Timothy J Kinsella; Kirill Kiselyov; Katsuhiko Kitamoto; Erwin Knecht; Masaaki Komatsu; Eiki Kominami; Seiji Kondo; Attila L Kovács; Guido Kroemer; Chia-Yi Kuan; Rakesh Kumar; Mondira Kundu; Jacques Landry; Marianne Laporte; Weidong Le; Huan-Yao Lei; Michael J Lenardo; Beth Levine; Andrew Lieberman; Kah-Leong Lim; Fu-Cheng Lin; Willisa Liou; Leroy F Liu; Gabriel Lopez-Berestein; Carlos López-Otín; Bo Lu; Kay F Macleod; Walter Malorni; Wim Martinet; Ken Matsuoka; Josef Mautner; Alfred J Meijer; Alicia Meléndez; Paul Michels; Giovanni Miotto; Wilhelm P Mistiaen; Noboru Mizushima; Baharia Mograbi; Iryna Monastyrska; Michael N Moore; Paula I Moreira; Yuji Moriyasu; Tomasz Motyl; Christian Münz; Leon O Murphy; Naweed I Naqvi; Thomas P Neufeld; Ichizo Nishino; Ralph A Nixon; Takeshi Noda; Bernd Nürnberg; Michinaga Ogawa; Nancy L Oleinick; Laura J Olsen; Bulent Ozpolat; Shoshana Paglin; Glen E Palmer; Issidora Papassideri; Miles Parkes; David H Perlmutter; George Perry; Mauro Piacentini; Ronit Pinkas-Kramarski; Mark Prescott; Tassula Proikas-Cezanne; Nina Raben; Abdelhaq Rami; Fulvio Reggiori; Bärbel Rohrer; David C Rubinsztein; Kevin M Ryan; Junichi Sadoshima; Hiroshi Sakagami; Yasuyoshi Sakai; Marco Sandri; Chihiro Sasakawa; Miklós Sass; Claudio Schneider; Per O Seglen; Oleksandr Seleverstov; Jeffrey Settleman; John J Shacka; Irving M Shapiro; Andrei Sibirny; Elaine C M Silva-Zacarin; Hans-Uwe Simon; Cristiano Simone; Anne Simonsen; Mark A Smith; Katharina Spanel-Borowski; Vickram Srinivas; Meredith Steeves; Harald Stenmark; Per E Stromhaug; Carlos S Subauste; Seiichiro Sugimoto; David Sulzer; Toshihiko Suzuki; Michele S Swanson; Ira Tabas; Fumihiko Takeshita; Nicholas J Talbot; Zsolt Tallóczy; Keiji Tanaka; Kozo Tanaka; Isei Tanida; Graham S Taylor; J Paul Taylor; Alexei Terman; Gianluca Tettamanti; Craig B Thompson; Michael Thumm; Aviva M Tolkovsky; Sharon A Tooze; Ray Truant; Lesya V Tumanovska; Yasuo Uchiyama; Takashi Ueno; Néstor L Uzcátegui; Ida van der Klei; Eva C Vaquero; Tibor Vellai; Michael W Vogel; Hong-Gang Wang; Paul Webster; John W Wiley; Zhijun Xi; Gutian Xiao; Joachim Yahalom; Jin-Ming Yang; George Yap; Xiao-Ming Yin; Tamotsu Yoshimori; Li Yu; Zhenyu Yue; Michisuke Yuzaki; Olga Zabirnyk; Xiaoxiang Zheng; Xiongwei Zhu; Russell L Deter
Journal:  Autophagy       Date:  2007-11-21       Impact factor: 16.016

10.  Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells.

Authors:  Eduardo C Filippi-Chiela; Emilly Schlee Villodre; Lauren L Zamin; Guido Lenz
Journal:  PLoS One       Date:  2011-06-13       Impact factor: 3.240

View more
  31 in total

1.  Plant stilbenes induce endoplasmic reticulum stress and their anti-cancer activity can be enhanced by inhibitors of autophagy.

Authors:  Ioanna Papandreou; Meletios Verras; Betina McNeil; Albert C Koong; Nicholas C Denko
Journal:  Exp Cell Res       Date:  2015-10-17       Impact factor: 3.905

2.  Pterostilbene down-regulates hTERT at physiological concentrations in breast cancer cells: Potentially through the inhibition of cMyc.

Authors:  Michael Daniel; Trygve O Tollefsbol
Journal:  J Cell Biochem       Date:  2017-12-26       Impact factor: 4.429

3.  Lysosomotropic agents selectively target chronic lymphocytic leukemia cells due to altered sphingolipid metabolism.

Authors:  R F Dielschneider; H Eisenstat; S Mi; J M Curtis; W Xiao; J B Johnston; S B Gibson
Journal:  Leukemia       Date:  2015-02-23       Impact factor: 11.528

4.  Pterostilbene simultaneously induced G0/G1-phase arrest and MAPK-mediated mitochondrial-derived apoptosis in human acute myeloid leukemia cell lines.

Authors:  Pei-Ching Hsiao; Ying-Erh Chou; Peng Tan; Wei-Jiunn Lee; Shun-Fa Yang; Jyh-Ming Chow; Hui-Yu Chen; Chien-Huang Lin; Liang-Ming Lee; Ming-Hsien Chien
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

5.  Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ.

Authors:  Kumar Nikhil; Shruti Sharan; Abhimanyu K Singh; Ajanta Chakraborty; Partha Roy
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  Estrogen receptor-α36 is involved in pterostilbene-induced apoptosis and anti-proliferation in in vitro and in vivo breast cancer.

Authors:  Chi Pan; Yiwang Hu; Jun Li; Zhaoyi Wang; Jianjin Huang; Suzhan Zhang; Ling Ding
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

Review 7.  Novel Approaches of Dysregulating Lysosome Functions in Cancer Cells by Specific Drugs and Its Nanoformulations: A Smart Approach of Modern Therapeutics.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Faris Alrumaihi; Saleh A Almatroodi; Mohammad O Alkurbi; Ghaiyda Talal Basfar; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  Int J Nanomedicine       Date:  2021-07-26

8.  Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells.

Authors:  Yang Yang; Xiaolong Yan; Weixun Duan; Juanjuan Yan; Wei Yi; Zhenxin Liang; Ning Wang; Yue Li; Wensheng Chen; Shiqiang Yu; Zhenxiao Jin; Dinghua Yi
Journal:  PLoS One       Date:  2013-05-03       Impact factor: 3.240

Review 9.  Role of Natural Stilbenes in the Prevention of Cancer.

Authors:  J Antoni Sirerol; María L Rodríguez; Salvador Mena; Miguel A Asensi; José M Estrela; Angel L Ortega
Journal:  Oxid Med Cell Longev       Date:  2015-12-21       Impact factor: 6.543

10.  BlueBerry Isolate, Pterostilbene, Functions as a Potential Anticancer Stem Cell Agent in Suppressing Irradiation-Mediated Enrichment of Hepatoma Stem Cells.

Authors:  Chi-Ming Lee; Yen-Hao Su; Thanh-Tuan Huynh; Wei-Hwa Lee; Jeng-Fong Chiou; Yen-Kuang Lin; Michael Hsiao; Chih-Hsiung Wu; Yuh-Feng Lin; Alexander T H Wu; Chi-Tai Yeh
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-26       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.